The short version
- Why people research itFat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
- What the evidence isIn phase 2.
- What to watchSevere headache with visual aura.
How Eloralintide works
Selective long-acting amylin receptor agonist (AMY1R-preferring) — appetite suppression via amylin pathways. More receptor-selective than cagrilintide.
This is the only compound in this cohort whose receptor selectivity ratio is actually published, so start there, because for a receptor-selective drug the ratio is the drug.
In cell lines expressing human receptors, eloralintide preferentially activated the human amylin 1 receptor: 12-fold over the calcitonin receptor and 11-fold over the amylin 3 receptor Briere 2025. Hold those numbers next to what the receptors are. AMY1 is the calcitonin receptor with RAMP1 bolted on; AMY3 is the same core with RAMP3 Boyle 2022.
- Injectable
Research on Eloralintide5 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Human clinical evidence
In phase 2. Eli Lilly's selective amylin receptor agonist. Early data reported meaningful weight loss with notably low rates of nausea and vomiting compared with GLP-1 agonists — which, if it holds, is the commercially important finding rather than the weight number.
Correlative data
No marketed use and no real-world record. The tolerability claim comes from small early cohorts and needs phase 3 scale before it means anything.
How the mechanism reads
A selective amylin analog — no GLP-1 activity at all, which is the point. Pramlintide proved amylin agonism causes weight loss twenty years ago.
MechanisticSelectivity is the bet on tolerability. If most of the GI burden comes from GLP-1's effect on gastric emptying, then an amylin-only agent should deliver satiety with less nausea — and that is precisely what the early data suggests.
MechanisticIt also predicts a smaller glycemic effect than a GLP-1, since amylin does not stimulate insulin secretion.
Mechanistic
Sources
- Briere DA, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Molecular Metabolism 2025 · PMID 41109426
- Billings LK, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2025 · PMID 41207310
- Bhattachar S, et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes, Obesity and Metabolism 2026 · PMID 41559929
- Boyle CN, Le Foll C, Lutz TA. Mediators of Amylin Action in Metabolic Control. Journal of Clinical Medicine 2022 · PMID 35456307
- Ghanizada H, et al. Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients. Annals of Neurology 2021 · PMID 33772845
- Stefanakis K, et al. The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation. Metabolism 2024 · PMID 39481534
- He L, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Internal Medicine 2022 · PMID 35344001
- Volcansek S, et al. Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity. Diabetes Therapy 2025 · PMID 40332747
- Muller TD, et al. Anti-obesity drug discovery: advances and challenges. Nature Reviews Drug Discovery 2022 · PMID 34815532
Eloralintide safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Migraine with aura, since amylin analog pramlintide has provoked migraine-like attacks.
- Insulin use, given amylin-class severe hypoglycemia warnings.
- Gastroparesis or erratic stomach emptying, which amylin agonism slows further.
- Pregnancy, as weight-loss appetite drive lowers nutrient intake.
- Under 18, where amylin-axis appetite suppression is untested.
What’s expected
- Appetite falls through amylin receptor action.
- Nausea, with no GLP-1 heart rate increase.
- Slower gastric emptying.
Watch for
- Severe headache with visual aura.
- Vomiting that persists beyond the first days of each change.
- Sweating and shakiness if used with glucose-lowering drugs.
Labs that tell you it’s working
- HbA1c: glucose control improves as weight falls.
- Comprehensive Metabolic Panel: kidney function and electrolytes if intake drops.
- Insulin (Fasting): AMY1R agonism does not itself raise insulin.
- Lipid Panel: triglycerides follow weight change.
Selective long-acting amylin receptor agonist (AMY1R-preferring) with no GLP-1 activity, so GLP-1 class risks do not transfer. PMID 41109426 PMID 41207310 PMID 33772845
Bloodwork to runHow you would know it is working: 8 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
Eloralintide FAQ4 common questions
- Is Eloralintide approved for human use?
- No. Eloralintide is a research compound.
- What is Eloralintide researched for?
- Fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
- Which labs show whether it's doing anything?
- HbA1c; Comprehensive Metabolic Panel; Insulin; Lipid Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Eloralintide: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.




